The maintenance of anti-Her2 antibody therapy and the potential long-term preservation of antibody-dependent cellular cytotoxicity may explain the risk attenuation and delayed relapse of Her2-positive breast cancer patients (36). The gene discussed is ERBB2; the disease is breast carcinoma.